MTOR INHIBITORS MARKET ANALYSIS

mTOR Inhibitors Market, by Drug Type (Everomilus, Temsirolimus, Siromilus), By Indication (Oncology, Immunosuppressant, Organ Transplant, Others), by Route of Administration (Oral, Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : May 2022
Code : CMI5019
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global mTOR Inhibitors Market – Region Analysis

On the basis of region, global mTOR inhibitors market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.

North America is expected to hold a dominant position in the market during the forecast period, owing to increasing number of product approvals from regulatory bodies in the region. For instance, in February 2016, Novartis AG, a pharmaceutical company, announced that the U.S.Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.